Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.

Optimizing SG&A: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Pfizer Inc. and Catalyst Pharmaceuticals, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, fluctuating around $14 billion annually. In contrast, Catalyst Pharmaceuticals has seen a dramatic increase, with expenses rising from approximately $4.5 million in 2014 to $133 million in 2023, marking a staggering 2,800% increase.

This divergence highlights the distinct strategies of these companies. Pfizer, a global leader, maintains a steady SG&A expenditure, reflecting its established market presence. Meanwhile, Catalyst's rising costs suggest aggressive expansion and investment in growth. Understanding these trends offers valuable insights into how pharmaceutical companies balance cost management with strategic growth.